Asset Details
Do you wish to reserve the book?
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
Do you wish to request the book?
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia
2020
Overview
Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications.
Publisher
Frontiers Media SA,Frontiers Media S.A
We currently cannot retrieve any items related to this title. Kindly check back at a later time.